RAD54L2

Across TCGA pan-cancer cohorts, RAD54L2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAD54L2 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RAD54L2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAD54L2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, HNSC, and CCRCC are the cancer types where RAD54L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	1.000	0.858	.004	22	view →
HNSC	OS	Quartile	All	0.773	0.969	.005	17	view →
CCRCC	OS	Tertile	All	0.841	1.000	.024	9	view →
LUAD	OS	Tertile	III,IV	1.000	0.421	.018	5	view →
GBM	DFS	Tertile	All	0.290	0.473	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAD54L2–LSCC (DFS)

Open the LSCC breakdown →